Neurodegenerative diseases are characterized by irreversible cell damage, loss of neuronal
cells and limited regeneration potential of the adult nervous system. Pluripotent stem cells …

Human embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs) hold
promise for transplantation medicine. Diverse human leukocyte antigen (HLA) profiles …

Human embryonic stem cells (hESCs) hold great promise for cell therapy as a source of
diverse differentiated cell types. One key bottleneck to realizing such potential is allogenic …

Human induced pluripotent stem cells (iPSCs) are promising in regenerative medicine.
However, the risks of teratoma formation and the overgrowth of the transplanted cells …

Current cancer treatments may create profound iatrogenic outcomes. The adverse effects of
these treatments still remain, as the serious problems that practicing physicians have to …

Tumorigenesis is an important problem that needs to be addressed in the field of human
stem/progenitor cell transplantation for the treatment of subacute spinal cord injury (SCI) …

Allogeneic immune rejection is a major barrier for the application of human pluripotent stem
cells (hPSCs) in regenerative medicine. A broad spectrum of immune cells, including T cells …

Background The advent of human-induced pluripotent stem cells holds great promise for
producing ample individualized hepatocytes. Although previous efforts have succeeded in …

Human induced pluripotent stem cells (hiPSC) hold promise for regenerative therapies,
though there are several safety concerns including the risk of oncogenic transformation or …

Iatrogenic tumorigenesis is a major limitation for the use of human induced pluripotent stem
cells (hiPSCs) in hematology. The teratoma risk comes from the persistence of hiPSCs in …